on M1 Kliniken AG (ETR:DE000A0S)
M1 Kliniken AG Completes Sale of HAEMATO Pharm GmbH to PHOENIX Group
Berlin-based M1 Kliniken AG has finalized the sale of its full subsidiary, HAEMATO Pharm GmbH, to the PHOENIX group. The transaction, completed at the end of January 2026, involved M1 Kliniken's majority stake through HAEMATO AG, which holds an 85% share. Key closing conditions, including antitrust approvals, have been satisfied, resulting in the deconsolidation of HAEMATO Pharm from HAEMATO AG and M1 Kliniken AG.
This strategic decision aligns with M1 Kliniken's mission to reinforce its position as a premier global provider specializing in medical aesthetics. M1 Kliniken AG, known for its network of 58 clinics across Europe and Australia, continues to bolster its presence in the sector.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all M1 Kliniken AG news